Home

Versant Venture Capital VII, L.P.

CIK 1750266 · last filed 2025-09-22

Versant Venture Capital VII, L.P. is a corporate insider who has filed 3 SEC Form 4 insider transactions across 2 companies since 2021. The most recent filing shows the insider sold $51.4M of LENZ on Sep 22, 2025. Across all open-market trades the lifetime net is −$179.4M, making them a net seller over the disclosed history. Current disclosed insider exposure totals $12.3M across reported positions. The firm reports its address in San Francisco, CA. 9 SEC filings were submitted jointly with Versant Vantage II GP, L.P.

"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.

Loading insider history…
Disclosed Exposure

$12.28M

Companies

2

Total Filings

3

Lifetime Open-Market Net

-$179.43M

Filer Profile

Reported Address
ONE SANSOME STREET, SUITE 1650
SAN FRANCISCO, CA 94104
Phone
(415) 801-8100
State of Incorporation
DE
Related Filers
Versant Vantage II GP, L.P. — 9 joint filings, latest 2025-10-02
Versant Vantage II GP-GP, LLC — 9 joint filings, latest 2025-10-02
Versant Venture Capital VI, L.P. — 9 joint filings, latest 2025-10-02
Versant Ventures VI GP, L.P. — 9 joint filings, latest 2025-10-02
Versant Ventures VI GP-GP, LLC — 9 joint filings, latest 2025-10-02
Versant Voyageurs I Parallel, L.P. — 4 joint filings, latest 2022-04-06
Versant Voyageurs I, L.P. — 4 joint filings, latest 2022-04-06
Versant Vantage I GP, L.P. — 1 joint filings, latest 2023-09-14
Profile details as reported on the filer's SEC submissions — for individual insiders the address is often in care of the issuer. Related filers are identified from jointly filed SEC submissions and shared reported addresses. View filings on SEC EDGAR.

Holdings By Company

Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
Symbol Role Shares Price Disclosed Exposure Lifetime OM Net Filings Latest Filed
LENZ 10%+ Owner 2,060,248 $5.96 $12.28M -$143.73M 2 2025-09-22
CHINOOK THERAPEUTICS, INC. (KDNY) Delisted 10%+ Owner 4,867,172 $40.39 $196.59M -$35.70M 1 2021-08-31

Recent Filings

3 filings
Insider activity across all companies, newest first. Form 4 rows are post-trade confirmations (buys, sells, grants, exercises). Notice (144) rows are pre-trade notices of intent to sell restricted or control stock under Rule 144 — they may not all execute. Compare adjacent dates to see which notices became actual sales.
Filed Symbol Action Net Shares Net $ Link
2025-09-22 LENZ Sell (S) −1,217,736 -$51.43M EDGAR
2025-08-19 LENZ Sell (S) −2,346,417 -$92.30M EDGAR
2021-08-31 CHINOOK THERAPEUTICS, INC. (KDNY) Delisted Sell (S) −2,550,000 -$35.70M EDGAR
Form 4 codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.